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cancer  incidence  and  the  involvement  of  EBV  in  some  of
these  tumors,  especially  lymphomas.  This  group  includes
PIDs  with  mutations  in  genes  WAS  (Wiskott--Aldrich  syn-
drome,  X-linked),  ATM  (Ataxia  telangiectasia  syndrome,  AR),
and  TNFRSF6  (ALPS-FAS,  AD  and  AR).2,4,6
The  message  for  all  pediatricians  is  to  consider  EBV  as  a
causative  agent  in  clinical  pictures  similar  to  those  described
by  Bolis  et  al.  In  addition  to  the  immune  system  impairment
associated  with  treatment  for  several  diseases,  we  must  also
consider  these  situations  as  a  red  alert  for  primary  immuno-
deﬁciencies  in  pediatric  patients.  Recognizing  PIDs  may  be
essential  to  achieve  a  better  management  for  patients  with
atypical  EBV  infections.
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Resposta dos autores: manifestac¸ões atípicas
do vírus de Epstein-Barr: alerta vermelho
para imunodeﬁciências primárias
Dear  Editor,
Human  primary  immunodeﬁciency  disease  (PID)  is  a  cond
tion  where  mutations  in  single  immune  system  gene
predispose  individuals  to  certain  infectious  agents.  Th
human  herpesviruses  are  a  challenge  of  immune  compe
tence,  since  most  of  these  agents  are  widespread  in  the
population;  they  are  often  acquired  silently  or  with  mild
symptoms  in  childhood  and  then  carried  for  life  as  asymp-
tomatic  latent  infections.  PID  patients  are  therefore  likely
to  be  exposed  to  these  viruses  relatively  early  in  life  and
will  have  to  deal  with  them  both  as  a  primary  infection
DOI of refers to article:
http://dx.doi.org/10.1016/j.jped.2016.05.002
 Please cite this article as: Bolis V, Karadedos C, Chiotis I,
Chaliasos N, Tsabouri S. Authors’ reply: Atypical manifestations
of Epstein--Barr virus: red alert for primary immunodeﬁciencies. J
Pediatr (Rio J). 2016;92:540--1.
a-
s:
ID
ry
o
V
5J Clin Immunol. 2015;35:696--726.
5. Fodil N, Langlais D, Gros P. Primary immunodeﬁciencies an
inﬂammatory disease: a growing genetic intersection. Tren
Immunol. 2016;37:126--40.
6. Cohen JI. Primary immunodeﬁciencies associated with EBV di
ease. Curr Top Microbiol Immunol. 2015;390:241--65.
Gesmar  R.S.  Segundo
Universidade  Federal  de  Uberlândia  (UFU),  Departamento
de  Pediatria,  Uberlândia,  MG,  Brazil
E-mail:  gesmar@famed.ufu.br
http://dx.doi.org/10.1016/j.jped.2016.05.002
and  as  a  persistent  condition.1 For  individuals  who  ar
immunocompromised,  due  to  a  genetic  immunodeﬁciency  o
immunosuppressive  drug  therapy,  viral  infections  may  resu
in  severe  complications  and  even  life-threatening  disease
PID  is  considered  a  rare  disease,  with  an  overall  inc
dence  of  4.6  cases  of  PIDs  per  100,000  person-years  in  th
last  35  years.3 However,  neither  the  true  incidence  nor  th
true  prevalence  of  PID  are  known.  Although  there  hav
been  estimates  of  these  parameters  from  geographical
limited  studies,  those  estimates  were  based  only  on  dia
nosed  cases.  Therefore,  PID  may  be  far  more  common  tha
previously  estimated.  Surveys  suggest  prevalence  rates  fo
diagnosed  PID  as  1:2000  for  children,  1:1200  for  all  person
and  1:600  households.4
Speciﬁc  gene  mutations  in  PID  patients  are  responsib
for  susceptibility  to  Epstein--Barr  virus  (EBV)  infections,  a
highlighted  in  the  letter  to  the  editor  of  the  Jornal  de  Pedi
tria  entitled  ‘‘Atypical  manifestations  of  Epstein--Barr  viru
red  alert  for  primary  immunodeﬁciencies’’.  Although  P
and  atypical  complications  of  EBV  infection  are  not  ve
common,  pediatricians  should  indeed  correlate  these  tw
conditions  as  mentioned  in  the  previous  letter,  since  EB
infects  more  than  95%  of  the  adult  population  worldwide.
PID  incidence  has  increased  in  the  last  decades,3 and
patients  with  immunodeﬁciency  are  the  group  most
exposed  to  atypical  complications  of  EBV  among  healthy
people.
The  strongest  predictor  of  PID  is  family  history.  Moreover,
when  an  immunodeﬁciency  disease  is  suspected,  initial  labo-
ratory  screening  should  include  a  complete  blood  count  with
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ferential  and  measurement  of  serum  immunoglobulin  and
mplement  levels.6
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